BACE1 and early-onset autosomal dominant Alzheimer disease: AZD3839, a synthetic compound, is reported to be used in the treatment of Alzheimer’s disease as it inhibits the activity of β-site amyloid precursor protein cleaving enzyme1 (BACE1), which is one of the key enzymes involved in the processing of amyloid precursor protein (APP) and the formation of amyloid β peptide (AβP) species [39].